Expedia Group, Inc.
$36.24B- Market cap
- $34.12B
- Debt
- +$7.85B
- Cash
- −$5.73B
Capital structure 81% equity / 19% debt · EV / Revenue 2.46x · EV / EBITDA 10.56x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 ·
Decision snapshot: EXPE stock price at discount vs ROIV $298.08 current versus $359.19K implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ROIV's multiple
Implied fair value · at EXPE's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: EXPE FY 2025 (ended Dec 31, 2025) · ROIV FY 2026 (ended Mar 31, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 81% equity / 19% debt · EV / Revenue 2.46x · EV / EBITDA 10.56x
Capital structure 98% equity / 2% debt · EV / Revenue 2586.72x
EXPE carries the larger enterprise value at $36.24B against $21.37B; EXPE trades on the lower EV / Revenue multiple (2.46x vs 2586.72x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
EXPEDIA GROUP, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ROIVANT SCIENCES LTD. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
6.12x
0.09x
Net debt / EBITDA
Leverage against operating earnings
0.62x
24.52x
Cash and equivalents
Liquid reserves on the balance sheet
$5.73B
$4.29B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Booking Holdings Inc.
EXPE vs BKNG
Airbnb, Inc.
EXPE vs ABNB
Delta Air Lines, Inc.
EXPE vs DAL
United Airlines Holdings, Inc.
EXPE vs UAL
Revolution Medicines, Inc.
EXPE vs RVMD
INCYTE CORP
EXPE vs INCY
Sarepta Therapeutics, Inc.
EXPE vs SRPT
EXELIXIS, INC.
EXPE vs EXEL
VERTEX PHARMACEUTICALS INC / MA
EXPE vs VRTX
$7.85B
$412.94M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.